Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Effect of Single Dose NP001 on Blood Markers of Inflammation in Individuals With Mild-to-Moderate Alzheimer's Disease

Trial Profile

Effect of Single Dose NP001 on Blood Markers of Inflammation in Individuals With Mild-to-Moderate Alzheimer's Disease

Discontinued
Phase of Trial: Phase I

Latest Information Update: 29 Oct 2018

At a glance

  • Drugs NP-001 (Primary)
  • Indications Alzheimer's disease
  • Focus Biomarker; Pharmacodynamics
  • Most Recent Events

    • 18 Oct 2018 Status changed from recruiting to discontinued.
    • 31 Aug 2018 Biomarkers information updated
    • 31 May 2018 Planned End Date changed from 31 Dec 2017 to 31 Jul 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top